NCT00047879View on ClinicalTrials.gov

Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Glioma
Interventions
BIOLOGICAL

PEG-interferon alfa-2b

0.3 µg/kg of IFN alfa-2b (PEG-Intron once weekly) plus daily oral thalidomide, subcutaneous injection

DRUG

Thalidomide

Two 50mg tablets (100 mg total dose) every night before bedtime starting on day one.

Trial Locations (1)

20892

National Institutes of Health, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00047879 - Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas | Biotech Hunter | Biotech Hunter